Quest Laboratories Ltd

QUESTLAB NSE Healthcare Pharmaceuticals
₹137.50
-1.47%
Delayed · cached 15 min

Fair value analysis

QUESTLAB
Quest Laboratories Ltd
HealthcarePharmaceuticals
₹83.95
Close used for this calculation
₹172.55Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
61/100
Profitability13/25
Returns17/25
Balance Sheet13/25
Efficiency18/25
Growth9/25
Good
Quality radar
61Prof.13/25Ret.17/25Eff.18/25B.Sht13/25Growth9/25

Consensus fair value

₹172.55
Below FV
▲ +105.5% against the close used
Model range ₹38.51 – ₹327.37
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹38.51Fair value₹172.55Bull₹327.37
FairClose
52-week traded range
52W low ₹82.0052W high ₹151.65

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

Quest Laboratories Ltd closed at ₹83.95, 51.3% below the consensus fair value of ₹172.55 drawn from 9 valuation models.

Financial DNA score 61/100 — Good. P/E of 9.2x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹138.11
+64.5%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=4.2%, r=10%, tg=3%, n=10yr
Graham Number
₹110.06
+31.1%
√(22.5 × EPS × BVPS)
EPS=9.17, BVPS=58.71
Graham Formula
₹143.90
+71.4%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=4.2%, FD=7%
P/E Fair Value
₹327.37
+290.0%
EPS × 35.7x (sector P/E)
EPS=9.17, Sector P/E=35.7x
Peter Lynch (PEG)
₹38.51
-54.1%
EPS × Growth% (PEG = 1 is fair)
EPS=9.17, g=4.2%
EV/EBITDA
₹134.02
+59.6%
(EBITDA × 12.1x − Net Debt) ÷ Shares
EBITDA=190M
Book Value (P/B)
₹127.53
+51.9%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=58.71, ROE=16.8%, g=4.2%, r=10%
Reverse DCF
₹83.95
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -3.6% | Historical: 4.2%
Margin of Safety
₹134.90
+60.7%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=179.86, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.